



Kyphoplasty and Vertebroplasty – Single Service

Clinical Guidelines for Medical Necessity Review

Version: 1.0
Effective Date: September 29, 2023

Important Notices

Notices & Disclaimers:

GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2023 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2022 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diseases & Disorders of the Musculoskeletal System (M00-M99)

Care Path Name: Kyphoplasty and Vertebroplasty – Single Service

Literature review current through: 9/29/2023

Document last updated: 9/29/2023

Type: ☒ Adult (18+ yo) | ☒ Pediatric (0-17yo)

Table of Contents

Important Notices	2
Table of Contents	3
Single Service & Medical Necessity Criteria	3
Surgical Management	3
Service: Kyphoplasty and Vertebroplasty for Vertebral Compression Fractures (VCF)	3
General Guidelines	3
Medical Necessity Criteria	4
Indications	4
Non-Indications	5
Site of Service Criteria	6
Procedure Codes (HCPCS/CPT)	6
Medical Evidence	7
References	9

Medical Necessity Criteria

Service: Kyphoplasty and Vertebroplasty – Single Service

General Guidelines

- **Units, Frequency, & Duration:** None.
- **Criteria for Subsequent Requests:** None.
- **Recommended Clinical Approach:** Kyphoplasty and vertebroplasty (or balloon-assisted vertebroplasty) involves injecting a bone cement (typically polymethylmethacrylate [PMMA]) into a vertebral body due to a vertebral compression fracture (VCF) or a disease process that has replaced the normal bony architecture. The cement provides stability to the damaged vertebra to reduce pain and improve function.
- **Exclusions:** Absolute exclusions include active infection at the surgical site or other systemic infection, allergies to bone cement, asymptomatic compression fractures, retropulsed bone fragment with spinal compromise, or nerve impingement.

Medical Necessity Criteria

Indications

- **Kyphoplasty and Vertebroplasty for Vertebral Compression Fractures (VCF)** is considered appropriate if **ALL** of the following are **TRUE**:
- ◆ Failure of conservative therapy, including **ANY** of the following:
 - Analgesics; **OR**
 - External orthosis; **OR**
 - Physical therapy; **OR**
 - Bed rest¹; **AND**
 - ◆ Acute (less than 6 weeks) or subacute (6-12 weeks) osteoporotic VCF (T1 – L5) as evidenced by **ALL** of the following:
 - Symptom onset; **AND**
 - Documented by advanced imaging (e.g., bone marrow edema on MRI or bone-scan/SPECT/CT uptake)²⁻⁹; **AND**
 - ◆ Symptomatic as evidenced by **ANY** of the following:³
 - Hospitalized with severe pain (Numeric Rating Scale [NRS] or Visual Analog Scale [VAS] pain score greater than or equal to 8)¹⁰⁻¹³; **OR**
 - Non-hospitalized with moderate to severe pain (NRS or VAS greater than or equal to 5) despite optimal non-surgical management (NSM) as evidenced by **ANY** of the following:⁷
 - Worsening pain; **OR**

- Stable to improved pain (but NRS or VAS still greater than or equal to 5) as evidenced by **TWO or more** of the following:
 - ◆ Progression of vertebral body height loss; **OR**
 - ◆ More than 25% vertebral body height reduction; **OR**
 - ◆ Kyphotic deformity; **OR**
 - ◆ Severe impact of VCF on daily functioning; **OR**
 - ◆ Roland Morris Disability Questionnaire (RDQ) greater than 17; **AND**
- ◆ The patient has **ANY** of the following indications:
 - Painful osteoporotic vertebral fracture(s) as evidenced by **ALL** of the following:¹⁴
 - Medically refractory pain (e.g., opioid intolerance); **AND**
 - Pain requiring a reduction in activities of daily living (ADLs); **AND**
 - Within 12 weeks of pain onset; **AND**
 - Remaining affected vertebra is more than one-third of the original vertebral height; **OR**
 - Vertebral bodies weakened by neoplasm¹⁴; **OR**
 - Symptomatic vertebral body microfracture as documented by advanced imaging without obvious loss of vertebral body height¹⁴; **OR**
 - Benign painful lesion of bone¹⁴; **OR**
 - Rapidly progressive fracture, with or without pseudoarthrosis potentially leading to kyphosis¹⁴; **OR**
 - Severe kyphosis resulting in decreased pulmonary function¹⁴; **OR**
 - Steroid-induced fracture; **OR**
 - Painful and/or aggressive hemangioma; **OR**
 - Painful multiple myeloma involving the vertebral body; **OR**
 - Painful osteolytic vertebral body metastatic disease; **OR**
- ◆ Continuum of care as evidenced by **ALL** of the following:^{2-3,7}
 - Referral for evaluation of a bone mineral density; **AND**
 - Referral to osteoporosis education for subsequent treatment as indicated; **AND**
 - Referral to an osteoporosis prevention/treatment program.

Non-Indications

→ **Kyphoplasty and Vertebroplasty for Vertebral Compression Fractures (VCF)** are not indicated if **ANY** of the following is **TRUE**:

- ◆ Osteoporotic VCF on imaging with correlating signs and symptoms and are neurologically not intact¹⁵; **OR**
- ◆ Patient has **ANY** of the following absolute contraindications:
 - Current back pain is not primarily due to the identified acute or subacute VCF(s)^{2-3,5,7,11-12}; **OR**
 - Osteomyelitis, discitis, active systemic or surgical site infection^{3,5,7,11-12,14}; **OR**
 - Infection along the intended trajectory of access¹⁴; **OR**
 - Septicemia¹⁴; **OR**
 - Uncorrectable coagulopathy¹⁴; **OR**
 - Asymptomatic compression fracture¹; **OR**
 - Allergy to cement or components of fill material; **OR**
 - Pregnancy; **OR**
- ◆ Patient has **ANY** of the following relative contraindications that have been evaluated and indicate that the procedure is not recommended:^{3,5,7,11,12}
 - Greater than three vertebral fractures per procedure; **OR**
 - Allergy to bone cement or opacification agents; **OR**
 - Uncorrected coagulopathy; **OR**
 - Spinal instability; **OR**
 - Myelopathy from the fracture; **OR**
 - Neurologic deficit; **OR**
 - Neural impingement; **OR**
 - Fracture retropulsion with canal compromise; **OR**
 - Radiculopathy, caused by a compressive syndrome unrelated to vertebral body fracture¹⁴; **OR**
 - Retropulsion of a fracture fragment with signs and/or symptoms of neurological compromise up to and including myelopathy or cauda equina syndrome¹⁴; **OR**
 - Epidural tumor extension with significant encroachment on the spinal canal¹⁴; **OR**
 - Fracture extension into the posterior vertebral body wall (risk of cement extravasation into the spinal canal)¹; **OR**
 - Patient with apparently stable fracture on imaging who is clinically improving¹⁴; **OR**

- Severe compression fractures or deformity¹; **OR**
- Prophylactic treatment for osteoporosis to prevent future fractures; **OR**
- Pregnancy.¹⁴

Site of Service Criteria

Inpatient or Outpatient.

Procedure Codes (HCPCS/CPT)

HCPCS Code	Code Description/Definition
01941	Anesthesia for percutaneous image-guided neuromodulation or intravertebral procedures (e.g., kyphoplasty, vertebroplasty) on the spine or spinal cord; cervical or thoracic
01942	Anesthesia for percutaneous image-guided neuromodulation or intravertebral procedures (e.g., kyphoplasty, vertebroplasty) on the spine or spinal cord; lumbar or sacral
22510	Percutaneous vertebroplasty of single cervicothoracic vertebral body with bilateral injection
22511	Percutaneous vertebroplasty of single lumbosacral vertebral body with bilateral injection
22512	Percutaneous vertebroplasty of each additional cervicothoracic vertebral body with bilateral injection
22513	Percutaneous augmentation of single thoracic vertebral body with insertion of mechanical device using cannula, including cavity creation
22514	Percutaneous augmentation of single lumbar vertebral body with insertion of mechanical device using cannula, including cavity creation
22515	Percutaneous augmentation of each additional lumbar vertebral body with insertion of mechanical device using cannula, including cavity creation

Medical Evidence

National and Professional Organizations

The **American Academy of Orthopaedic Surgeons (AAOS)** published a clinical practice guideline on the *Treatment of Symptomatic Osteoporotic Spinal Compression Fractures*. Kyphoplasty is for neurologically intact patients with an osteoporotic spinal compression fracture, as evidenced by imaging with clinical symptoms. The AAOS does provide a recommendation of support or non-support regarding the improvement of kyphosis angle in patients with an osteopathic spinal compression fracture.¹⁶

The **American College of Radiology (ACR)**, **American Society of Neuroradiology (ASNR)**, **American Society of Spine Radiology (ASSR)**, **Society of Interventional Radiology (SIR)**, and the **Society of NeuroInterventional Surgery (SNIS)** published a *Practice Parameter for the Performance of Vertebral Augmentation*. The document includes indications, contraindications, and specifications of the procedure.¹⁴ The **ACR** also published *Appropriateness Criteria: Management of Vertebral Compression Fractures*.¹⁷

The **Society of Interventional Radiology (SIR)** issued a position statement on percutaneous vertebral augmentation in collaboration with the **American Association of Neurological Surgeons (AANS)**, **Congress of Neurological Surgeons (CNS)**, **American College of Radiology (ACR)**, **American Society of Neuroradiology (ASNR)**, **American Society of Spine Radiology (ASSR)**, **Canadian Interventional Radiology Association (CIRA)**, and **Society of NeuroInterventional Surgery (SNIS)**. The Societies support percutaneous vertebral augmentation (PVA) with the use of vertebroplasty or kyphoplasty as a safe, effective, and durable procedure in appropriate patients with symptomatic osteoporotic and neoplastic fractures.⁴

The **National Comprehensive Cancer Network (NCCN)** published a clinical practice guideline on *Multiple Myeloma*. Vertebroplasty or kyphoplasty is indicated for vertebral compression fractures.¹⁸

The **International Society for the Advancement of Spine Surgery (ISASS)** published a policy on *Vertebral Augmentation*. Vertebroplasty and kyphoplasty are supported for the early treatment of painful VCFs. The ISASS does not endorse any specific vertebroplasty/ kyphoplasty system.¹⁹

The **National Institute for Health and Care Excellence (NICE)** published the *Technology Appraisal Guidance: Percutaneous Vertebroplasty and Percutaneous Balloon Kyphoplasty for Treating Osteoporotic Vertebral Compression Fractures*. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty without stenting are recommended to treat osteoporotic vertebral compression fractures in patients:¹⁰

- “Who have severe ongoing pain after a recent, unhealed vertebral fracture despite optimal pain management; and
- In whom the pain has been confirmed to be at the level of the fracture by physical examination and imaging.”

References

1. Jay B, Ahn SH. Vertebroplasty. *Semin Intervent Radiol*. 2013 Sep;30(3):297–306. doi: 10.1055/s-0033-1353483. PMID: 24436552; PMCID: PMC3773069.
2. Centers for Medicare and Medicaid Services (CMS). Local coverage determination: Percutaneous vertebral augmentation (PVA) for vertebral compression fracture (VCF) (L34976). Effective Date October 1, 2015. Accessed September 18, 2023. <https://www.cms.gov/medicare-coverage-database/search.aspx>.
3. Centers for Medicare and Medicaid Services (CMS). Local coverage determination: Percutaneous vertebral augmentation (PVA) for osteoporotic vertebral compression fracture (VCF) (L33569). Effective Date October 1, 2015. Accessed September 18, 2023. <https://www.cms.gov/medicare-coverage-database/search.aspx>.
4. Barr JD, Jensen ME, Hirsch JA, et al. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS). *J Vasc Interv Radiol*. 2014 Feb;25(2):171–81. doi: 10.1016/j.jvir.2013.10.001. PMID: 24325929.
5. Tsoumakidou G, Too CW, Koch G, et al. CIRSE guidelines on percutaneous vertebral augmentation. *Cardiovasc Intervent Radiol*. 2017 Mar;40(3):331–342. doi: 10.1007/s00270-017-1574-8. PMID: 28105496.
6. McConnell CT, Jr., Wippold FJ, 2nd, Ray CE, Jr., et al. ACR appropriateness criteria management of vertebral compression fractures. *J Am Coll Radiol*. 2014 Aug;11(8):757–63. doi: 10.1016/j.jacr.2014.04.011. PMID: 24935074.
7. Hirsch JA, Beall DP, Chambers MR, et al. Management of vertebral fragility fractures: a clinical care pathway developed by a multispecialty panel using the RAND/UCLA appropriateness method. *Spine J*. 2018 Nov;18(11):2152–2161. doi: 10.1016/j.spinee.2018.07.025. PMID: 30096377.
8. Clark W, Bird P, Diamond T, et al. Cochrane vertebroplasty review misrepresented evidence for vertebroplasty with early intervention in severely affected patients. *BMJ Evid Based Med*. 2020 Jun;25(3):85–89. doi: 10.1136/bmjebm-2019-111171. PMID: 30852489; PMCID: PMC7286037.
9. De Leacy R, Chandra RV, Barr JD, et al. The evidentiary basis of vertebral augmentation: A 2019 update. *J Neurointerv Surg*. 2020 May;12(5):442–447. doi: 10.1136/neurintsurg-2019-015026. PMID: 31974279.

10. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures [TA279]. Published April 24, 2013. Accessed September 18, 2023. <https://www.nice.org.uk/guidance/ta279>.
11. Clark W, Bird P, Gonski P, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): A multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2016 Oct 1;388(10052):1408-1416. doi: 10.1016/S0140-6736(16)31341-1. PMID: 27544377.
12. Chandra RV, Maingard J, Asadi H, et al. Vertebroplasty and kyphoplasty for osteoporotic vertebral fractures: What are the latest data? *AJNR Am J Neuroradiol*. 2018 May;39(5):798-806. doi: 10.3174/ajnr.A5458. PMID: 29170272; PMCID: PMC7410658.
13. Firanesescu CE, de Vries J, Lodder P, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. *BMJ*. 2018;361:k1551. doi: <https://doi.org/10.1136/bmj.k1551>.
14. American College of Radiology (ACR). ACR-ASNR-ASSR-SIR-SNIS practice parameter for the performance of vertebral augmentation. Revised 2022. Accessed September 18, 2023. [https://www.acr.org/-/media/ACR/Files/Practice-Parameters/vertebral aug.pdf](https://www.acr.org/-/media/ACR/Files/Practice-Parameters/vertebral_aug.pdf).
15. Patel D, Liu J, Ebraheim NA. Managements of osteoporotic vertebral compression fractures: A narrative review. *World J Orthop*. 2022 Jun 18;13(6):564-573. doi: 10.5312/wjo.v13.i6.564. PMID: 35949707; PMCID: PMC9244957.
16. Esses SI, McGuire R, Jenkins J, et al. The treatment of symptomatic osteoporotic spinal compression fractures. *J Am Acad Orthop Surg*. 2011 Mar;19(3):176-82. doi: 10.5435/00124635-201103000-00007. PMID: 21368099.
17. American College of Radiology (ACR). ACR Appropriateness Criteria: Management of Vertebral Compression Fractures. Revised 2022. Accessed September 18, 2023. <https://acsearch.acr.org/docs/70545/Narrative/>.
18. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Multiple myeloma (ver. 4.2023). Published August 25, 2023. Accessed September 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
19. Clerk-Lamallice O, Beall DP, Ong K, et al. ISASS policy 2018 - vertebral augmentation: Coverage indications, limitations, and/or medical necessity. *Int J Spine Surg*. 2019 Feb 22;13(1):1-10. doi: 10.14444/5096. PMID: 30805279; PMCID: PMC6383452.

Clinical Guideline Revision History/Information

Original Date: September 29, 2023	
Review History	